Zevra Therapeutics, Inc. · NASDAQ:ZVRA
Zevra Therapeutics — Kempharm — Corporate Update (December 2019)
11 slides from Zevra Therapeutics's corporate update, Dec 18, 2019
Slide 1: December 2019 Debt Restructuring
December 18, 2019 December 2019 Debt Restructuring Exhibit 99.2
Slide 2: Cautionary Note Regarding Presentation Information
Cautionary Note Regarding Presentation Information This presentation contains forward-looking statements, including statements regarding the timing of the KP415 NDA filing, the probability of being accepted for review by the FDA, the potential label for KP415, the potential approval timing for KP415
Slide 3: Call Participants
Travis Mickle, Ph.D. – President & Chief Executive Officer R. LaDuane Clifton, CPA – Chief Financial Officer, Secretary & Treasurer Gordon K. “Rusty” Johnson – Chief Business Officer Call Participants
Slide 4: Today's Updates
Today’s Updates December 2019 Debt Restructuring Deerfield/KemPharm Drug Discovery Collaboration KP415 NDA Timeline Next Steps
Slide 5: Addressing Debt: A Two Stage Approach (Before)
Addressing Debt: A Two Stage Approach Note Holder(s) Principal Coupon and Maturity Dates Convert Strike Price 2014 Senior Notes Deerfield $7.0M 6.75% Feb 14, 2020 and Jun 1, 2020 $5.85 2021 Convertible Notes Deerfield $62.4M 5.50% Feb 1, 2021 $17.11 Delaware Street Capital $8.3M Other holder(s) $3.0
Slide 6: Addressing Debt: A Two Stage Approach (After Exchanges)
Addressing Debt: A Two Stage Approach Note Holder(s) Principal Coupon and Maturity Dates Convert Strike Price 2014 Senior Notes Deerfield $7.0M 6.75% Mar 31, 2021 $5.85 2019 Senior Notes Deerfield $62.4M 6.75% Mar 31, 2021 $17.11 Delaware Street Capital $8.3M 2021 Convertible Notes Other holder(s) $
Slide 7: Extension of convertible note maturities to March 31, 2021
Working with our two largest convertible note holders, we have pushed out the principal and interest payments due on $77.7M of our outstanding convertible notes until March 31, 2021 which is past the potential approval date of our first partnered ADHD product candidate, KP415 The maturity date of De
Slide 8: Amended September 2019 Exchange Agreement
The September 2019 Exchange Agreement has been amended as follows: Optional Exchange Price has been adjusted to the greater of (i) the 15-day VWAP as of date the option is used, or (ii) $0.60 (from $0.9494) Maximum common shares to be issued remains limited to 28.4M, but the limit on the amount of n
Slide 9: Deerfield – KemPharm Drug Discovery Collaboration
Deerfield, or its affiliates, may identify up to two compounds with applications for new disease indications, and KemPharm will utilize its proprietary technology to potentially discover acceptable new product candidates for development Potentially create new prodrugs designed to: Improve profile of
Slide 10: KP415 NDA Timelines and Partnership Update
KP415 NDA Timelines and Partnership Update Review of every NDA section is nearing completion Mutual goal for both KemPharm and GPC is to file the KP415 NDA ASAP We continue to believe that the two primary goals of the NDA submission should be (i) achieving the highest probability of NDA acceptance f
Slide 11: Next Steps
Next Steps Maximize the value of our license agreements for both KP415/KP484 and APADAZ® GPC optional product candidates: KP879 and KP922 APADAZ now available File the KP415 NDA as soon as possible Continue supporting commercial launch preparation for KP415 If requested, initiate work with Deerfield